1st Quarter - Report
RIVENDELL GROUP LLP for GENENTECH
Firm
Client
Income
$30,000
Expenses
—
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Drug pricing under 340B program and drug pricing issues generally; Legislation related to repeal and replace of the Affordable Care Act (H.R. 1628 American Healthcare Act of 2017); PDUFA
| Lobbyist | Covered position, as disclosed |
|---|---|
| MATTHEW LAWRENCE BERZOK | LD and Chief Counsel, Rep. Bart Stupak; LA, Rep. Peter Deutsch |
| NICK KOLOVOS | LA and Counsel, Rep. Anna Eshoo |
Health Issues HCR
Drug pricing under 340B program and drug pricing issues generally; Legislation related to repeal and replace of the Affordable Care Act (H.R. 1628 American Healthcare Act of 2017); PDUFA
| Lobbyist | Covered position, as disclosed |
|---|---|
| MATTHEW LAWRENCE BERZOK | LD and Chief Counsel, Rep. Bart Stupak; LA, Rep. Peter Deutsch |
| NICK KOLOVOS | LA and Counsel, Rep. Anna Eshoo |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.